8-K: Telesis Bio Announces Second Quarter 2024 Results, Revenue Declines Amid Restructuring

Telesis Bio reported a significant decrease in revenue for the second quarter of 2024, alongside restructuring efforts and a strategic divestiture.

Summary

• Telesis Bio announced its financial results for the second quarter and first half of 2024, highlighting a strategic shift towards its Gibson SOLA platform.
• The company divested its Eton subsidiary, which is now reflected as a discontinued operation in the financial statements.
• Second-quarter revenue was $1.6 million, a decrease from $7.0 million in the same period last year, with product revenue down $1.8 million and collaboration revenue down $3.5 million.
• The gross margin was -52%, compared to 71% in the prior year, primarily due to $1.8 million in restructuring charges; excluding these charges, the gross margin would have been 64%.
• Operating expenses were $10.7 million, a 14% improvement from the prior year, and would have been $8.8 million excluding restructuring charges, representing a 30% reduction.
• The net loss for the quarter was $13.2 million, compared to a loss of $8.4 million in the same period last year, with a net loss per share of $7.62.
• As of June 30, 2024, the company had $10.3 million in cash, cash equivalents, restricted cash, and investments, and $5.3 million in notes payable.
• The company is not issuing additional forward-looking guidance at this time.

Sentiment

Score: 3

Explanation: The document indicates a significant decline in revenue and a substantial net loss, despite cost-cutting measures. The lack of forward guidance adds to the uncertainty, resulting in a negative sentiment.

Positives

• The company is advancing its Gibson SOLA platform, which is gaining market interest.
• Operating expenses decreased by 14% year-over-year, and by 30% excluding restructuring charges.
• The company is actively pursuing its strategic research collaboration with Pfizer.
• Restructuring efforts are expected to have a substantial positive impact on future quarters.

Negatives

• Second-quarter revenue decreased significantly to $1.6 million from $7.0 million year-over-year.
• The gross margin was -52% for the quarter, impacted by restructuring charges.
• The net loss for the quarter was $13.2 million, compared to a loss of $8.4 million in the same period last year.
• The company's cash position decreased to $10.3 million from $19.3 million at the end of 2023.

Risks

• The company's transition to Gibson SOLA as its primary focus has led to a reduction in product revenue.
• The timing of milestone completion under strategic collaborations has impacted collaboration revenue.
• Restructuring activities resulted in significant non-recurring expenditures in the second quarter.
• The company is not issuing additional forward-looking guidance at this time, indicating uncertainty about future performance.

Future Outlook

The company will not be issuing additional forward-looking guidance at this time.

Management Comments

• The company undertook a variety of additional restructuring activities tied to further reducing its cost base across all areas of the business.
• The goal of this process was to align our cost structure to current market conditions and our focus on commercial adoption of Gibson SOLA.
• The favorable impact on future quarters will be substantial relative to Company spending levels of recent years.

Industry Context

The company's focus on automated DNA and mRNA synthesis aligns with the growing trend in the biotechnology industry towards rapid and efficient therapeutic discovery and development. The strategic collaboration with Pfizer highlights the potential of their technology in the mRNA-based vaccine and biopharma space.

Comparison to Industry Standards

• Telesis Bio's revenue decline is significant compared to other companies in the biotech sector, which often experience growth or stable revenue during similar periods.
• The negative gross margin of -52% is concerning, as most biotech companies aim for positive gross margins, especially those with commercialized products.
• Companies like Twist Bioscience and Ginkgo Bioworks, which are also involved in synthetic biology, have shown different financial trajectories, with some experiencing revenue growth and others focusing on strategic partnerships.
• The restructuring efforts and cost reductions are a common strategy in the biotech industry to manage expenses and focus on core technologies, but the magnitude of the impact on Telesis Bio's financials is notable.

Management Changes

Stakeholder Impact

• Shareholders will be negatively impacted by the significant decrease in revenue and increased net loss.
• Employees may have been affected by the restructuring activities, including potential job losses.
• Customers may experience changes in product availability and focus due to the shift towards Gibson SOLA.
• Suppliers may be impacted by the company's cost-cutting measures.

Next Steps

• The company will continue to focus on the commercial adoption of its Gibson SOLA platform.
• Telesis Bio will continue to pursue activities under its strategic research collaboration with Pfizer.

Key Dates

Keywords

Gibson SOLA, DNA synthesis, mRNA synthesis, restructuring, financial results, revenue, gross margin, operating expenses, net loss, Pfizer collaboration, biotechnology